Therapy-Related Myelodysplastic Syndrome Recruiting Phase 1 Trials for Ibrutinib (DB09053)

IndicationStatusPhase
DBCOND0079186 (Therapy-Related Myelodysplastic Syndrome)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03359460Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic SyndromeTreatment